BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 125117
Published online Nov 24, 2026. doi: 10.5306/wjco.125117
Figure 1
Figure 1 Study flow diagram. LASSO: Least absolute shrinkage and selection operator; pT4: Pathological T4.
Figure 2
Figure 2 Least absolute shrinkage and selection operator-Cox variable selection. A: Ten-fold cross-validation with standard-error bars and the minimum-error and one-standard-error penalties; B: Standardized coefficient paths.
Figure 3
Figure 3 Apparent time-dependent receiver operating characteristic curves at 36 months and 60 months. AUC: Area under the receiver operating characteristic curve; CI: Confidence interval.
Figure 4
Figure 4 Apparent calibration and decision curves. A: Calibration at 36 months; B: Calibration at 60 months. Predicted disease-free survival event risks are compared with observed risks by risk quintile, and dashed lines indicate ideal calibration; C: Decision-curve analysis at 36 months; D: Decision-curve analysis at 60 months. Decision curves compare the proposed model, the TNM-only comparator, and treat-all and treat-none strategies. The TNM-only comparator includes pathological T4 subtype and pN stage. DFS: Disease-free survival.
Figure 5
Figure 5 Kaplan-Meier disease-free survival curves for groups defined by the median centered linear predictor. Shading indicates pointwise 95% confidence intervals.
Figure 6
Figure 6 Nomogram for 36-month and 60-month disease-free survival event risk. Total predictor points are mapped to the 36-month and 60-month disease-free survival event-risk axes. The nomogram represents all eight regression terms across seven clinical-variable axes; pN stage is encoded by separate pN1 and pN2 indicator terms, with pN0 as the reference. DFS: Disease-free survival; ASA: American Society of Anesthesiologists; CA19-9: Carbohydrate antigen 19-9.


Write to the Help Desk